Intranasal Delivery to the Central Nervous System: Mechanisms and Experimental Considerations

Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, USA.
Journal of Pharmaceutical Sciences (Impact Factor: 3.01). 01/2009; 99(4):1654-73. DOI: 10.1002/jps.21924
Source: PubMed

ABSTRACT The blood-brain barrier (BBB) limits the distribution of systemically administered therapeutics to the central nervous system (CNS), posing a significant challenge to drug development efforts to treat neurological and psychiatric diseases and disorders. Intranasal delivery is a noninvasive and convenient method that rapidly targets therapeutics to the CNS, bypassing the BBB and minimizing systemic exposure. This review focuses on the current understanding of the mechanisms underlying intranasal delivery to the CNS, with a discussion of pathways from the nasal cavity to the CNS involving the olfactory and trigeminal nerves, the vasculature, the cerebrospinal fluid, and the lymphatic system. In addition to the properties of the therapeutic, deposition of the drug formulation within the nasal passages and composition of the formulation can influence the pathway a therapeutic follows into the CNS after intranasal administration. Experimental factors, such as head position, volume, and method of administration, and formulation parameters, such as pH, osmolarity, or inclusion of permeation enhancers or mucoadhesives, can influence formulation deposition within the nasal passages and pathways followed into the CNS. Significant research will be required to develop and improve current intranasal treatments and careful consideration should be given to the factors discussed in this review.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Intracerebral hemorrhage (ICH) is a very complex pathology, with many different not fully elucidated etiologies and prognostics. It is the most severe subtype of stroke, with high mortality and morbidity rates. Unfortunately, despite the numerous promising preclinical assays including neuroprotective, anti-hypertensive, and anti-inflammatory drugs, to this moment only symptomatic treatments are available, motivating the search for new alternatives. In this context, stem cell therapy emerged as a promising tool. However, more than a decade has passed, and there is still much to be learned not only about stem cells, but also about ICH itself, and how these two pieces come together. To date, rats have been the most widely used animal model in this research field, and there is much more to be learned from and about them. In this review, we first summarize ICH epidemiology, risk factors, and pathophysiology. We then present different methods utilized to induce ICH in rats, and examine how accurately they represent the human disease. Next, we discuss the different types of stem cells used in previous ICH studies, also taking into account the tested transplantation sites. Finally, we summarize what has been achieved in assays with stem cells in rat models of ICH, and point out some relevant issues where attention must be given in future efforts.
    04/2015; 7(3):618. DOI:10.4252/wjsc.v7.i3.618
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to investigate the protective role of intranasally administered substance P-loaded gelatin nanoparticles (SP-GNPs) against 6-hydroxydopamine (6-OHDA)-induced apoptosis in vitro and in vivo, and to provide a new strategy for treating brain pathology, such as Parkinson's disease. SP-GNPs were prepared by a water-in-water emulsion method, and their stability, encapsulating efficiency, and loading capacity were evaluated. PC-12 cells were used to examine the enhancement of growth and inhibition of apoptosis by SP-GNPs in vitro using MTT assays. In the in vivo study, hemiparkinsonian rats were created by intracerebroventricular injection of 6-OHDA. The rats then received intranasal SP-GNPs daily for 2 weeks. Functional improvement was assessed by quantifying rotational behavior, and the degree of apoptosis was assessed by immunohistochemical staining for caspase-3 in the substantia nigra region. PC-12 cells with 6-OHDA-induced disease treated with SP-GNPs showed higher cell viability than their untreated counterparts, and cell viability increased as the concentration of substance P (SP) increased, indicating that SP could enhance cell growth and inhibit the cell apoptosis induced by 6-OHDA. Rats with 6-OHDA-induced hemiparkinsonism treated with SP-GNPs made fewer rotations and showed less staining for caspase-3 than their counterparts not treated with SP, indicating that SP protects rats with 6-OHDA-induced hemiparkinsonism from apoptosis and therefore demonstrates their functional improvement. Intranasal delivery of SP-GNPs protects against 6-OHDA-induced apoptosis both in vitro and in vivo.
    Drug Design, Development and Therapy 01/2015; 9:1955. DOI:10.2147/DDDT.S77237 · 3.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The treatment of central nervous system diseases is very difficult due to the inability of drugs to permeate into the brain from the bloodstream. The intranasal route of administration allows for rapid drug delivery directly from the nasal mucosa to the brain, minimizing systemic exposure. Chitosan is one of the most used excipient for nasal formulations due to its mucoadhesive and penetration enhancement properties. Several chitosan formulations have been proposed for the nose-to-brain delivery of drugs (solutions, suspension, gels, microemulsion, and powers). Particulate formulations can offer advantages over liquid medication, such as greater stability, greater convenience, and long residence time of the drug in the nasal cavity. This review provides a summary and discussion of recent data on nasal particulate formulations based on chitosan, its salts, and derivatives for nose-to-brain delivery of drugs. We also summarize the drugs studied for this administration route and the preparation methods of these formulations.
    Journal of Drug Delivery Science and Technology 05/2015; DOI:10.1016/j.jddst.2015.05.002 · 1.09 Impact Factor


Available from
May 23, 2014